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Abstract
Background: Clostridium difficile is one of the major nosocomial threats causing severe gastrointestinal infections.
Compared to the well documented clinical symptoms, little is known about the processes in the bacterial cell like
the regulation and activity of metabolic pathways. In this study, we present time-resolved and global data of
extracellular substrates and products. In a second part, we focus on the correlation of fermentation products and
substrate uptake with toxin production.
Results: Formation of different fermentation products during growth in a comparison between the two different
media in a global approach was studied using non-targeted gas chromatography–mass spectrometry (GC-MS)
based analysis. During cultivation in a casamino acids medium and minimal medium, the clinical isolate C. difficile
630Δerm showed major differences in amino acid utilization: In casamino acids medium, C. difficile preferred
proline, leucine and cysteine as carbon and energy sources while glutamate and lysine were not or hardly used. In
contrast, proline and leucine were consumed at a significantly later stage in minimal medium. Due to the more
complex substrate mixture more fermentation products were detectable in the casamino acids medium,
accompanied by major changes in the ratios between oxidative and reductive Stickland products. Different glucose
consumption dynamics were observed in presence of either casamino acids or the minimal set of amino acids,
accompanied by major changes in butanoate formation. This was associated with a variation in both the toxin yield
and a change in the ratio of toxin A to toxin B.
Conclusions: Since in all media compositions, more than one substrate was available as a suitable carbon source,
availability of different carbon sources and their metabolic fate appears to be the key factor for toxin formation.
Keywords: Clostridium difficile, Metabolism, Stickland reaction, Amino acids, Fermentation products, Toxin
Background
Clostridium difficile is one of the major nosocomial
pathogens and causes antibiotic-associated diarrhoea
and pseudomembranous colitis through its toxins. The
major risk factor for a C. difficile infection is the expos-
ure to antibiotics. The normal microflora of the gut is
destroyed by the administration especially of broad-
spectrum antibiotics allowing colonization and growth
of C. difficile [1, 2].
The strain C. difficile 630Δerm used in this study was
constructed by Hussain et al. [3] and is based on the strain
630 isolated during an outbreak in Switzerland and was
first described in 1983 [4]. Toxin production is associated
with dramatic changes in the bacterial metabolism and is
linked to availability of substrates such as glucose, cysteine
or proline [5]. Thus, detailed understanding of its metab-
olism and substrate preferences is an essential perquisite
for the development of new therapeutic strategies.* Correspondence: m.neumann-schaal@tu-braunschweig.de
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Similar to a number of anaerobic bacteria, C. difficile
has developed specific pathways to degrade amino acids
and sugars by fermentation processes [6–8]. Due to the
absence of any respiratory system, in this process energy
is conserved mainly by substrate-level phosphorylation.
Fermentation of amino acids is summarized under the
name “Stickland reactions” involving the coupled oxida-
tion and reduction of amino acids to their corresponding
organic acids [9]. The electron donor amino acid is oxi-
dized to a carboxylic acid one carbon atom shorter than
the original amino acid while the electron acceptor
amino acid is reduced to the corresponding deaminated
carboxylic acid with the same length as the original
amino acid. Specific amino acids can act as Stickland ac-
ceptors (reductive pathway, Fig. 1, light grey), Stickland
donors (oxidative pathway, Fig. 1, dark grey), or as both.
Some amino acids are known to follow modified path-
ways e.g. proline and glycine [10–13]. Early studies with
different C. difficile isolates revealed its ability to pro-
duce Stickland products e.g. from leucine, isoleucine,
valine, phenylalanine and tyrosine [6, 7]. On enzymatic
level, Stickland reactions were studied in C. difficile with
a special focus on leucine [14, 15]. More extensive stud-
ies were performed on C. sticklandii and C. sporogenes
focussing on aromatic amino acids [16, 17].
Toxigenic C. difficile strains produce up to three major
toxins [18]. Toxins A and B are members of the large
clostridial toxin family which comprises various toxins
from different Clostridia [19]. A third toxin is described
as the CDT binary toxin, however it is not present in the
strain 630 [20]. Toxin A and B are large single-chain
mono-glucosyltransferases catalyzing the glycosylation
and thereby the inactivation of Rho-GTPases leading to
cell death [19, 21]. In addition to the genes of the toxins
themselves, the genome of toxigenic C. difficile includes
related genes encoding the positive regulator TcdR
Fig. 1 Generalized view of Stickland reactions. Light grey panel: reductive pathway, dark grey panel: oxidative pathway, R depending on the
amino acid. Products and intermediates that may be detectable in the supernatant and are thus discussed below are labelled with red letters
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essential for toxin expression [22, 23], the antagonist
TcdC [24] and the holin-like protein TcdE required for
release from the cell [25].
While influence on growth and toxin formation of sin-
gle substrates added to complex media is characterized
[5–7, 26, 27], only a small number of studies focus on C.
difficile grown in defined and minimal media. First stud-
ies on defined and minimal medium were performed by
Haslam et al. [28] and Karasawa et al. [29]. All authors
described major differences between different clinical
and ecological isolates in deprivation experiments in
media containing 18 amino acids: while all tested strain
require isoleucine, leucine, valine and proline for growth,
only some of them show detectable growth in the
absence of either tryptophan [29], methionine, or cyst-
eine [29]. Arginine, glycine, histidine and threonine were
classified as growth-enhancing amino acids [29]. Minimal
requirements for growth were defined by Karlsson et al.
[30]. Jackson et al. [13] could show that L-4-hydroxyproline
can replace L-proline in defined medium as a Stickland ac-
ceptor. However, hydroxyproline is not a direct substrate
for D-proline reductase, so an intracellular conversion of
hydroxyproline to proline via a yet unclear way is required.
Addition of certain amino acids such as proline and glycine
were only enhancing growth addition in presence of selen-
ium due to the involvement of selenoenzymes, e.g. proline
reductase and glycine reductase, in the catabolism of these
amino acids.
Here, we present the first time-resolved and global
study of consumption and export of metabolites in-
volved in C. difficile 630Δerm fermentation in a defined
casamino acid containing medium and in a minimal
medium including a detailed view on metabolism-
dependent toxin production. We give a detailed insight
into the formation of different fermentation products
during growth in a comparison between the two differ-
ent media in a global approach using non-targeted gas
chromatography–mass spectrometry (GC-MS) based
analysis.
Results and discussion
Growth curve and glucose consumption in different
media
C. difficile 630Δerm [3] showed a significantly altered
growth in the casamino acids containing C. difficile Min-
imal Medium (CDMM) compared to Minimal Defined
Medium (MDM) (Fig. 2a). While growth in CDMM
showed a clear exponential growth phase, growth in
MDM appeared to be more linear. Fitting of the growth
curves revealed doubling times of 29.7 min and 48.3 min,
respectively. The maximal optical density (OD600nm) dif-
fered from 1.4 in CDMM to 0.45 in MDM. Both media
contained 2 g/L of glucose and 4.63 g/L and 3.6 g/L of
amino acid mixtures, respectively (Tables 1 and 2). A sig-
nificant pH shift was not observed in any culture (pH 6–7
at the end of cultivation). So, amino acid composition ap-
peared to be crucial for the observed biomass yield. Based
on the genome annotation, in addition to glucose only
cysteine is available for biomass formation in MDM.
Other amino acids in this medium, such as branched
chain amino acids, tryptophan and proline, are most likely
only used as energy source in Stickland reactions and for
protein biosynthesis since C. difficile lacks appropriate
degradation pathways connected to the central carbon
metabolism [20, 31]. A similar energy metabolism was
also observed for related Clostridia such as C. sticklandii
[16]. More experimental data supporting this speculation
are summarized in the chapter Time-resolved amino acid
uptake.
Fig. 2 Growth curves and glucose consumption of C. difficile 630Δerm on CDMM and MDM. a Optical densities were measured at 600 nm of at
least 10 different biological replicates; squares represent growth in CDMM, circles in MDM. b Glucose concentration in the culture supernatant
after growth in different media. Concentration was determined enzymatically as described in Methods, squares/black line represent
concentrations in CDMM, circles/grey line in MDM, curves were fitted according to the Boltzmann model using Origin9.0G software
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Glucose was completely consumed in both, MDM and
CDMM, but the dynamics differed significantly (Fig. 2b).
Omitting glucose from the medium led to a significantly re-
duced ODmax of 0.16 ± 0.02 in MDM but not in CDMM.
In CDMM no significant consumption of glucose was ob-
served until the end of exponential growth followed by a
rapid uptake. By the end of the transition phase, glucose
concentrations were already below detection limit. In
MDM, glucose was consumed over the whole growth curve
with only 27 % of the maximal uptake rate compared to
CDMM (Tables 1 and 2, Additional files 1 and 2).
Time-resolved amino acid uptake
C. difficile showed a very complex preference for the dif-
ferent amino acids in the two media used. The most in-
teresting result is the fact that out of the amino acids
available in CDMM, the most abundant one, glutamate,
was not used despite its internal important role as an
amino-group transferring agent and its internal high
concentration. On the other hand, the fact that aspartate
was used indicates a high specificity of the aspartate/glu-
tamate-transporter (CD630_25410) for aspartate, consid-
ering the high glutamate concentration in the medium
Table 1 Substrate uptake of amino acids and glucose supplied in CDMM
Substrate Initial concentration Relative abundance in stationary phase thalfmaximal comsumption Maximal relative uptake rate
g/L % min h−1
Glucose 2.0 bdla 246 ± 3 0.61 ± 0.07
Proline 0.36 bdl 106 ± 4 0.32 ± 0.02
Cysteine 0.5 bdl 124 ± 4 0.43 ± 0.03
Aspartate 0.27 16.3 ± 0.9 141 ± 8 0.34 ± 0.04
Arginine 0.14 35.7 ± 0.9 148 ± 7 0.20 ± 0.02
Alanine 0.16 19.4 ± 2.8 157 ± 11 0.23 ± 0.02
Leucine 0.38 bdl 161 ± 4 0.49 ± 0.08
Glycine 0.05 bdl 163 ± 7 0.31 ± 0.02
Tryptophan 0.1 45.7 ± 1.0 167 ± 15 0.12 ± 0.01
Serine 0.25 bdl 167 ± 2 0.62 ± 0.03
Isoleucine 0.24 bdl 170 ± 5 0.33 ± 0.02
Methionine 0.12 bdl 170 ± 7 0.45 ± 0.03
Tyrosine 0.24 25.7 ± 0.6 171 ± 17 0.19 ± 0.02
Threonine 0.21 bdl 177 ± 18 0.21 ± 0.01
Phenylalanine 0.20 bdl 177 ± 4 0.44 ± 0.01
Valine 0.27 5.4 ± 0.3 224 ± 13 0.24 ± 0.03
Lysine 0.34 101.0 ± 2.1 No significant consumption
Glutamate 0.80 97.6 ± 3.9 No significant consumption
Composition of casamino acids is based on distribution of amino acids in casein and was confirmed by enzymatic assays (for detailed procedure see Additional file 4);
total sampling range up to 660 min, for detailed fits, see Additional file 1; abdl, below detection limit
Table 2 Substrate uptake of amino acids and glucose supplied in MDM
Substrate Initial concentration Relative abundance in stationary phase thalfmaximal comsumption Maximal relative uptake rate
g/L % min h−1
Glucose 2.0 bdla 197 ± 10 0.17 ± 0.01
Methionine 0.2 bdl 136 ± 17 0.23 ± 0.04
Cysteine 2.0 bdl 164 ± 13 0.21 ± 0.01
Isoleucine 0.3 18.4 ± 0.8 306 ± 18 0.11 ± 0.01
Tryptophan 0.1 bdl 307 ± 23 0.13 ± 0.01
Proline 2.0 bdl 318 ± 4 0.56 ± 0.05
Leucine 0.4 27.2 ± 0.2 332 ± 8 0.16 ± 0.01
Valine 0.3 36.3 ± 0.9 347 ± 8 0.18 ± 0.02
Total sampling range up to 720 min, for detailed fits, see Additional file 2; abdl, below detection limit
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(Table 1, Additional file 1) (compare also [27]). Lysine
was also not utilized.
The import of the other available amino acids is highly
diverse with rapidly imported ones (Ser, Met, Leu, Pro),
amino acids with 50 % consumption in the middle of the
exponential growth phase (Gly, Ile, Phe, Thr) and less effi-
ciently used ones (Trp, Arg, Tyr, Ala, Asp, Val) (Table 1,
Additional file 1). Independent from the overall rate of
consumption most of the amino acids are imported from
the start of the growth phase whereas valine was only
slowly consumed in the beginning and much quicker later
when rapidly used substrates were below detection limit.
Apparently, valine is not a preferred substrate though it is
subjected to oxidative Stickland fermentation and essential
for C. difficile 630Δerm.
In the MDM only 7 amino acids are available for growth
(Pro, Cys, Met, Val, Leu, Ile, Trp). Due to conflicting evi-
dence obtained in C. difficile isolates in former deprivation
studies [28, 29], we tested the essentiality of each of the
seven amino acids. Except for a minimal growth observed
in the absence of methionine, no growth was observed in
the absence of each of the others (data not shown).
In time-dependent studies, cysteine and methionine
were consumed from the start of growth. Proline was
consumed only slowly in the beginning with a rapid con-
sumption starting in the middle of the exponential phase
(Table 2, Additional file 2). As in CDMM, tryptophan
was consumed almost linearly during the whole growth.
Different preferences were observed for branched chain
amino acids: while a clear order of preferences in CDMM
was observable (leucine, isoleucine, valine), the three con-
sumption curves were quite similar in MDM. None of
them was consumed completely (Table 2, Additional file
2). This indicates that the entry into the stationary phase
is not caused by a lack of energy sources but by the lack of
a carbon source usable for biomass production. To verify
this assumption, we added threonine solution to the cul-
ture at the beginning of the stationary phase which re-
sulted in a restart of growth. The presence of branched
chain amino acids has been previously shown to influence
DNA-binding affinities of the global regulator CodY so
that consumption of these amino acids is supposed to
have major influences on the enzyme repertoir and
thereby on the metabolism [32, 33].
C. difficile shares a high genomic similarity with C. stick-
landii, and thus a similar energy metabolism was assumed
in the literature [16] but in this study we could show sig-
nificant differences in amino acid utilization and fermen-
tation product formation. Secretion of alanine was only
observed in MDM but not in medium with more amino
acids (CDMM) and no secretion of glutamate or aspartate
was detected. Aspartate was actually consumed by C. diffi-
cile. Branched chain amino acids, especially leucine are
preferred substrates of C. difficile but not of C. sticklandii.
Lysine is consumed by C. sticklandii at a late stage of
growth, but not by C. difficile under our growth
conditions.
Metabolite export during growth
Analogous to substrate consumption, a defined order
was observed for fermentation product formation. Over-
all, we could detect 25 different products exported dur-
ing growth in CDMM (Table 3, Additional file 3). For
some products the origin is obvious: as the reductive
Stickland products (Fig. 1d), 5-aminovalerate was pro-
duced from proline, isocaproate from leucine and 3-
phenylpropanoate from phenylalanine. The product of
tyrosine 3-(4-hydroxyphenyl)propanoate was detectable
only in traces (data not shown). Additional oxidative
Stickland products (Fig. 1b) occurred in CDMM: isovale-
rate produced from leucine, (4-hydroxyphenyl)acetate from
tyrosine, 2-methylbutanoate from isoleucine, isobutanoate
from valine and phenylacetate from phenylalanine. Also
some intermediates of the Stickland reactions were detect-
able in the supernatant: 2-oxo-isocaproate (Fig. 1a), 3-(4-
hydroxyphenyl)lactate and 3-phenyllactate (both Fig. 1c).
This is surprising since it is not energetically favourable.
This is possibly due to either an imbalance of the oxidative
and reductive pathways or an unspecific export of the inter-
mediates. A number of fermentation products is produced
via acetyl-CoA and/or propanoyl-CoA: acetate, valerate,
propanoate, butanoate, and 3-hydroxybutanoate. Acetyl-
CoA is formed from several sources, e.g. threonine, glycine,
serine, alanine and glucose. Propanoyl-CoA is produced
from e.g. threonine and methionine. Later in growth, also
different alcohols occurred in the supernatant (Table 3).
2-Aminobutanoate and 2-hydroxybutanoate originate
from the intermediate 2-oxobutanoate, which occurs in
threonine and methionine degradation, both were first de-
tectable at the same time of the growth curve. 2-
Aminobutanoate could be one form of exporting excess ni-
trogen from the cell. Additionally, ammonium was found
in the supernatant released via deamination from all amino
acids except for proline, leading to an ammonium forma-
tion in both MDM and CDMM (Tables 3 and 4). The for-
mation of 2-aminobutanoate was described earlier for C.
difficile in complex media [8]. Formate was produced either
via 2-oxobutanoate or from pyruvate by formate-C-
acetyltransferase (EC 2.3.1.54) yielding propanoyl-CoA or
acetyl-CoA, respectively [31].
In the MDM-culture, the fermentation product profile
was less complex (Table 4, Additional file 2). As in CDMM,
2-methylbutanoate, isobutanoate, isocaproate and isovale-
rate were produced from branched chain amino acids and
5-aminovalerate from proline. As intermediates 2-oxo-
isocaproate (Fig. 1a) and additionally 2-hydroxyisocaproate
(Fig. 1c) were detectable. In the stationary phase, also low
amounts of 2-oxo-isovalerate and 3-methyl-2-oxovalerate
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Table 3 Exported metabolites detected in growth with CDMM
Product tfirst detection thalfmaximal production Maximal relative production rate
min min h−1
Isovalerate 60 83 ± 5 0.59 ± 0.02
Propanoate 80 120 ± 8 0.39 ± 0.01
2-oxo-isocaproate 90 155 ± 12 0.26 ± 0.08
(4-hydroxyphenyl)acetate 150 161 ± 12 0.39 ± 0.04
5-aminovalerate 60 163 ± 7 0.33 ± 0.03
2-methylbutanoate 60 168 ± 13 0.45 ± 0.05
Acetate 90 175 ± 6 0.30 ± 0.02
3-(4-hydroxyphenyl)lactate 175 181 ± 5 0.78 ± 0.14
Isocaproate 60 194 ± 7 0.47 ± 0.05
Isobutanoate 60 202 ± 5 0.59 ± 0.04
Ammonium traces in medium 210 ± 28 0.19 ± 0.04
2-aminobutanoate 150 213 ± 6 0.28 ± 0.02
Formate 60 228 ± 10 0.24 ± 0.01
Phenylacetate 60 231 ± 4 0.38 ± 0.03
Ethanol 210 259 ± 6 0.32 ± 0.04
3-hydroxybutanoate 240 261 ± 7 0.62 ± 0.13
p-cresol 60 263 ± 9 0.26 ± 0.02
2-hydroxybutanoate 150 273 ± 4 0.30 ± 0.03
1-butanol 225 274 ± 9 0.39 ± 0.03
Isobutanol 240 276 ± 8 0.46 ± 0.03
Butanoate 175 285 ± 6 0.30 ± 0.04
Valerate 175 315 ± 4 0.25 ± 0.06
3-phenylpropanoate 175 355 ± 9 0.21 ± 0.06
Lactate 225 364 ± 3 0.27 ± 0.02
3-phenyllactate 120 387 ± 21 0.12 ± 0.01
All compounds with the exception of formate and ammonium were detected by GC-MS; formate and ammonium were quantified by enzymatic assays
(see Methods), total sampling range up to 660 min, for detailed fits, see Additional file 3
Table 4 Product formation in MDM
Product tfirst detection thalfmaximal production Maximal relative production rate
min min h−1
Formate 30 202 ± 18 0.16 ± 0.02
2-hydroxyisocaproate 135 225 ± 12 0.21 ± 0.02
Isocaproate 90 239 ± 14 0.14 ± 0.01
Isobutanoate 135 258 ± 39 0.12 ± 0.02
Isovalerate 30 280 ± 9 0.13 ± 0.02
2-methylbutanoate 30 290 ± 43 0.11 ± 0.01
5-aminovalerate 210 360 ± 8 0.21 ± 0.02
2-oxoisocaproate 280 435 ± 16 0.15 ± 0.02
Alanine 280 442 ± 18 0.18 ± 0.01
Acetate 280 457 ± 20 0.12 ± 0.01
Ammonium traces in medium 470 ± 49 0.11 ± 0.01
All compounds with the exception of formate and ammonium were detected by GC-MS; formate and ammonium were quantified by enzymatic assays
(see Methods), total sampling range up to 720 min, for detailed fits, see Additional file 2
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were detectable corresponding to the 2-ketoacids derived
from valine and isoleucine (Fig. 1a).
In contrast to CDMM, no butanoate formation was
observed in MDM. This is in accordance with the fact
that in CDMM more sources for biomass formation are
available (e.g. threonine, serine, glycine). Accordingly,
also short-chain alcohol formation was not detectable in
the MDM-culture.
Moreover, qualitative analysis showed that both sulfite
and sulfide were produced in MDM and CDMM (data
not shown).
Time-dependent leucine fermentation in
CDMM and MDM
Leucine as a Stickland amino acid is of special interest
since it can be metabolized by the oxidative and reduc-
tive pathway [14, 15]. In the first growth phase the major
exported product from leucine was isovalerate (Fig. 3a).
Then the intermediate of both pathways, 2-oxo-
isocaproate was found in the supernatant before the
reductive product isocaproate was detectable in the
supernatant. Maximal isovalerate concentration was
already reached at a stage where 25 % of the initial leu-
cine was still available. Though isocaproate was also de-
tectable in the early growth phase, major isocaproate
production started when the concentrations of other
substrates for reductive fermentation such as proline
and glycine concentrations were already significantly
reduced (25 % and 50 %, respectively). In MDM, no clear
temporal separation was observable (Fig. 3b): isocaproate
and isovalerate were exported simultaneously. In
contrast to CDMM, the reductive intermediate 2-
hydroxyisocaproate was detectable during growth in
MDM. 2-oxo-isocaproate was also detectable but exported
later in growth compared to isocaproate.
While isocaproate and isovalerate showed a compar-
able abundance in chromatograms obtained from sam-
ples in CDMM cultures (Fig. 4a), the most abundant
fermentation product in MDM was isovalerate with the
peak area of isocaproate being only 2 % of that from iso-
valerate. The change between the different media was
dramatic indicating that reductive fermentation in MDM
was mainly covered by proline yielding 5-aminovalerate
and that all exported isovalerate originated from leucine
and not from valine.
This agrees with the enzyme characterization of the
purified enzymes, involved in C. difficile leucine
degradation, ((R)-2-hydroxyisocaproate dehydrogenase,
(R)-2-hydroxyisocaproate-CoA transferase and 2-
hydroxyisocaproyl-CoA dehydratase). The putative val-
ine fermentation intermediate 2-oxoisovalerate was not
accepted as a substrate by (R)-2-hydroxyisocaproate de-
hydrogenase [14, 15]. Moreover, we did not observe the
putative product of isoleucine, 3-methylvalerate, in the
supernatant.
Time-dependent phenylalanine degradation in CDMM
Phenylalanine belongs also to those amino acids, that
can be degraded via Stickland reaction, both oxidatively
and reductively (Fig. 1). The growth curve revealed a
preference for phenylalanine as a substrate for oxidative
Stickland reaction. Phenylacetate was already detectable
60 min after the end of the lag-phase, i.e. at the beginning
of the exponential growth phase (Fig. 5). The reductive
intermediate 3-phenyllactate was detectable 60 min later
and the final reductive product 3-phenylpropanoate
115 min later. Phenylalanine as both oxidative and reduc-
tive substrate is rather unusual among clostridia. For C.
sporogenes, C. botulinum, and C. sticklandii only one of
them, either phenylacetate or 3-phenylpropanoate as
product was found [7, 34]. In an earlier study with a
Fig. 3 Leucine fermentation of C. difficile 630Δerm on CDMM and MDM. Left axis: black circles, leucine; blue triangles, isovalerate; red squares,
2-oxo-isocaproate; green rhombs, isocaproate; light green octagons, 2-hydroxyisocaproate; right axis: dotted line, growth curve; curves were fitted
according to the Boltzmann model using Origin9.0G software. a Leucine consumption and fermentation product formation in CDMM. b Leucine
consumption and fermentation product formation in MDM
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different C. difficile isolate in complex medium, 3-
phenyllactate was not detected in the supernatant [7]. The
detailed analysis of the total amounts accumulated in the
supernatant in the stationary phase revealed that C. diffi-
cile produced both phenylalanine fermentation products
in similar amounts with a tendency to higher amounts of
the reductive product 3-phenylpropanoate (Fig. 4b).
C. difficile contains only one operon coding for genes
of the classical reductive Stickland degradation (ldhA
and hadAIBC, locus-tag CD630_03940 to _03980) [31].
Though the specific function was assigned to leucine
degradation, earlier in vitro studies showed an activity of
the (R)-2-hydroxyisocaproate dehydrogenase (LdhA) for
phenylpyruvate (corresponding to Fig. 1a) [14, 15]. Thus,
most likely aromatic acids are fermented with the same
set of enzymes as leucine. Our data show that significant
reductive phenylalanine fermentation was only observed
when extracellular leucine levels dropped below 10 % of
the initial concentration. As observed for leucine, the
intermediate product 3-phenyllactate (Fig. 1c) was
exported earlier than the final product. These data are in
accordance with enzymatic in vitro data which revealed
a higher affinity of the (R)-2-hydroxyisocaproate de-
hydrogenase to 2-oxo-isocaproate (the intermediate of
leucine fermentation) compared to phenylpyruvate [15]
and clearly support a physiological role for the metabol-
ism not only of leucine but also of phenylalanine.
Toxin formation in CDMM and MDM
Toxin formation is typically characterized in cultures
48–72 h after inoculation. Earlier during growth, toxin
detection is possible rather intracellularly than in the
supernatant [30]. Toxin formation was determined with
Fig. 4 Detected relative amounts of leucine and phenylalanine fermentation products in stationary phase. a White bars: isocaproate, grey bars:
isovalerate. Determined in non-derivatized samples after ether extraction by GC/MS, peak areas were determined using MetaboliteDetector software
and were normalized on the relative proportion of the specific quantification ion and the internal standard o-cresol added prior to extraction. b White
bar, 3-phenylpropanoate, grey bar, phenylacetate. Determined in derivatized samples after drying by GC/MS. Peak areas were determined using
MetaboliteDetector software and were normalized on ribitol and the relative proportion of the specific quantification ion added as internal standard
prior to drying procedure. We cannot exclude differences of the two compounds during extraction, drying or derivatization procedures
Fig. 5 Phenylalanine fermentation of C. difficile 630Δerm on CDMM.
black circles, phenylalanine; blue triangles, phenylacetate; red squares,
3-phenylpropanoate; green rhombs, 3-phenyllactate; dotted line,
growth curve; curves were fitted according to the Boltzmann model
using Origin9.0G software
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an ELISA assay in the exponential, transient and early sta-
tionary phase and after 48 h of growth (Fig. 6). We did
not observe detectable toxin concentrations extracellularly
during the exponential and transient growth phase in
CDMM and not until late stationary phase in MDM.
Intracellularly, toxins were detectable earlier during
growth in both media. In CDMM, Toxin A was quantified
with 175.2 ± 3.2 ng and Toxin B with 10.0 ± 0.6 ng
exported per mg of dry biomass until late stationary
phase. Toxin A was quantified with 31.17 ± 0.06 ng and
Toxin B with 1.53 ± 0.05 ng exported per mg of dry bio-
mass in MDM. The ratio Toxin A to Toxin B was 18 in
CDMM compared to 20 in MDM.
Toxin production varies dramatically between different
isolates of C. difficile and different publications [30, 35, 36]
and quantification of toxins depends on the quantification
method and its feasibility of calibration. Comparison of the
extracellular toxin level of five different strains including
strain 630 revealed the lowest toxin scores for C. difficile
630 in a complex medium after 24 h cultivation with a
toxin A to toxin B ratio of 1.4 [36]. Especially the ratio of
Toxin A and Toxin B differs dramatically from our data ob-
tained for C. difficile 630Δerm in defined media. Appar-
ently, medium composition and tested growth phase
influence not only the total amounts of toxin but also the
ratio between toxin A and B. The change of ratio is espe-
cially interesting since toxin B is considered to be 100-
1000-fold more cytotoxic than toxin A [19, 37].
While neither growth phase nor growth rate had a dra-
matic effect on toxin production of the strain VPI 10463,
glucose limitation reduced toxin yields 20- to 100-fold in
defined media [30]. Effects of glucose vary depending on
the medium between a toxin-repressing effect in rich
media and an enhancing one in defined media [26, 30]. Ef-
fects of specific amino acids are also largely depending on
the basic medium as shown for cysteine and a mixture of
nine amino acids [5, 30]. Among these nine amino acids
were essential amino acids such as the branched chain
amino acids, proline and tryptophan. Branched chain
amino acids are known to increase the binding affinity of
the global regulator CodY to the tcdR promotor region of
the pathogenicity locus thereby repressing toxin synthesis
in rich media [32, 33]. Earlier studies especially with C.
difficile VPI 10463 revealed that different defined media
with amino acid compositions comparable to MDM and
CDMM had little influence on intracellular toxin forma-
tion [30]. Comparing the total toxin yield (intra- and
extracellular), results were different: while a medium com-
parable to CDMM (MDM supplemented with threonine,
glycine and casamino acids) yielded a much higher total
toxin production ranging between the yields obtained in
the complex PY and PYG media [30], MDM supple-
mented with threonine and glycine yielded significantly
lower toxin yields [5]. Here, we observed a similar effect
for strain 630Δerm. Moreover, we could show that not
only the absolute concentration but also the ratio of both
toxins is altered.
A significant interconnection between butanoate forma-
tion and toxin formation due to coupled regulation was
discussed mainly for C. difficile strain VPI 10463 [5].
Bouillaut et al. speculated that this link may be a response
to high intracellular NADH levels or to other gastrointes-
tinal bacteria producing butanoate [38]. Our results show
dramatic differences in the butanoate production between
Fig. 6 Toxin formation in CDMM and MDM. Toxin A (a, dark grey bars) and Toxin B (b, light grey bars) was determined in culture supernatants
(extra) and intracellularly (intra) in the exponential, transient and early stationary phase and after 48 h of cultivation (from left to right) using an
immunoassay and was calculated per mg of C. difficile dry weight, * below detection limit
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two defined media. In the absence of butanoate formation,
we observed 5.6-fold lower toxin A and 6.5-fold lower
toxin B formation despite the presence of equal amounts
of glucose in the medium. A link to intracellular NADH
levels is supported by the low toxin levels in MDM where
leucine as one of preferred reductive substrates is still
available in the stationary phase thereby preventing excess
reducing equivalents. Basically, these data support a co-
regulation of genes of toxin and butanoate formation but
it clearly indicates that focussing on a single substrate it-
self is not an appropriate indicator for effects on toxin
production.
Conclusions
Our analysis of amino acid utilization demonstrated that C.
difficile degrades amino acids in a highly complex, but de-
fined way, depending on the composition of the medium.
The data generated with casamino acids containing
medium showed that proline, leucine and cysteine are the
preferred sources of energy and carbon whereas glutamate
and lysine are not or hardly used. Comparison of amino
acid preferences in different media revealed that two of the
preferred substrates in CDMM, proline and leucine were
consumed in MDM at a later stage of growth while cysteine
and methionine were consumed first. Our data show that
C. difficile is optimal adapted to conditions observed in the
intestine: Growth in more complex media such as CDMM
is not dependent on monosaccharides as carbon source
since their availability is limited in the large intestine [39].
C. difficile reaches high doubling rates almost comparable
to respiring bacteria under appropriate conditions and is
specialized on amino acids that are not so commonly used
by other bacteria: like branched chain and aromatic amino
acid as well as hydroxyproline. A typical and widely used
amino acid such as glutamate is not a substrate of C. diffi-
cile (for a comparison with other human-pathogenic and
environmental bacteria see [40–42]).
Due to the severe influence of amino acids on toxin for-
mation, some authors suggested effects with regard to in-
fection and therapy [28, 30, 43]. Our data suggest that
toxin formation is less dependent on the presence of glu-
cose in the medium than on its metabolic fate in C. diffi-
cile when different defined media were supplemented with
glucose and cysteine. Since both cysteine and glucose are
suitable carbon sources, availability of different carbon
sources also in complex media could be one of the key
factors for toxin formation. Thus, an isolated view on sin-
gle substrates will not lead to a detailed understanding of
the underlying regulation. Detailed and global analysis of
the metabolic changes involved in toxin formation will
give detailed insights into the metabolic fate of available
substrates to establish a metabolic indicator useful for
therapy development.
Methods
Strains, media and growth conditions
All studies were carried out with C. difficile 630Δerm
(DSM28645) [3] obtained from the Deutsche Sammlung
von Mikroorganismen und Zellkulturen (DSMZ, Braun-
schweig, Germany). Strain maintenance was performed
routinely by growing the cells in anaerobized brain-heart-
infusion medium in an anaerobic chamber (95 % N2/
5 % H2) and cells were checked for antibiotic sensitivity
on a regular basis.
CDMM is a defined medium containing glucose and
casamino acids as carbon and energy sources and was pre-
pared as described by Cartman and Minton [44] with fol-
lowing modifications: NaHCO3 was replaced by NaH2PO4
and a final concentration of 1 μM sodium hydrogensele-
nite was added (according to [13]), the glucose and biotin
concentrations were reduced to 2 g/L and 0.012 mg/L,
respectively (according to [30]) and the tryptophan con-
centration was reduced to 0.1 g/L. Casamino acids were
obtained from Roth (Carl Roth GmbH, Karlsruhe,
Germany). MDM contains seven essential amino acids
(isoleucine, leucine, valine, tryptophan, cysteine, methio-
nine and proline) and glucose as carbon and energy
sources and was prepared as described by Karlsson et al.
[30] with following modifications: NaHCO3 was replaced
by NaH2PO4 and a final concentration of 1 μM sodium
hydrogenselenite was added (according to [13]), cysteine
and proline concentrations were increased to 2 g/L.
Cells were passaged twice with a dilution in MDM or
CDMM as required of at least 1:100 prior to inoculation
of the main culture.
Main cultures were inoculated at an OD600nm of ~ 0.005
and growth at 37 °C was determined by following the op-
tical density at 600 nm. Due to differences in the lag-
phases of biological replicates, cultures were lag-phase
corrected. Samples at different time points were taken an-
aerobically from at least 10 biological replicates. Samples
for further analysis were taken throughout the whole
growth curve.
Enzymatic assays
L-amino acids (except glycine) were quantified using the
L-Amino Acid Quantitation Kit (Sigma-Aldrich, St.
Louis, MO, USA). Glucose, glutamate, formate and am-
monium were assayed using R-biopharm yellow line kits
(D-glucose, glutamic acid, formic acid and ammonia).
Due to interference of supernatant components with the
glucose assay, sample preparation prior to glucose quan-
tification had to be modified. For the modified sample
preparation, we included a drying step under vacuum at
50 °C and resolving the dried sample in water. Spiking
experiments revealed a recovery of 91–99 % of added
glucose.
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Alanine was quantified by an enzymatic assay with L-
alanine dehydrogenase from Bacillus cereus (Sigma-Aldrich,
St. Louis, MO, USA) as described in [45] with the minor
modifications. NADH formation was followed at 340 nm
with 700 μL carbonate buffer pH 10, 100 μL of sample,
100 μL 20 mM NAD and 100 μL L-alanine dehydrogenase
solution 0.5 U/mL for 5 min. For validation a 1 mg/mL L-
Alanine was used whereby concentration ranges between
0.01 and 0.2 mg/mL.
The distribution of amino acids in casamino acids is
based on the protein sequences of bovine casein [46]. The
theoretical ratio between alanine and glutamate (0.2) was
confirmed by enzymatic assays (0.2). The concentrations
of the remaining amino acids were calculated based on
the experimentally determined concentration of alanine
and confirmed by determination of free L-amino acids
(except glycine). Details are listed in Additional file 4.
Toxin quantification
Toxins A and B were quantified using the TGC-E002-1
ELISA (tgcBIOMICS GmbH, Bingen, Germany) for the
separate detection of Toxin A and Toxin B. For intracel-
lular toxin levels cells were lysed according to [30]. The
supernatant of harvested samples was used immediately.
Gas chromatography/mass spectrometry based analysis
of volatile compounds
The extraction and GC method was adapted from Su et al.
[47] including several modifications: 1/5 volume of HPLC-
grade sulphuric acid and o-cresol as internal standard were
added to the culture supernatant and volatile compounds
were extracted by vigorously mixing with 200 μL of tert-
methylbutylether. After centrifugation at 4 °C, 10 min and
8000 g, the ether phase was transferred into a GC-MS vial
and 1 μL of the extract was injected into a Thermo DSQ II
gas chromatograph equipped with a liner and quadrupol
mass spectrometer. Chromatography was carried with an
Agilent VF-WAXms column (30 m length, 0.25 mm inner
diameter, Agilent, Santa Clara, CA, USA) at a constant flow
of 1 mL/min helium. The temperature program started at
55 °C held for 1 min, followed by temperature ramping of
10 °C min to a final temperature of 250 °C, which was held
constant for 2 min. Solvent delay time was 2.4 min. A re-
tention index marker (n-alcanes ranging from C10…C22 in
cyclohexane) was used to convert retention times to reten-
tion indices.
Gas chromatography/mass spectrometry based analysis
of non-volatile compounds
10 μL of the supernatant was mixed with 500 μL ethanol
spiked with 4 μg/mL of ribitol as internal standard. For
further sample preparation, derivatization and measure-
ment, samples were treated as described in Reimer et al.
[48] with minor modifications: During the derivatization
procedure the Gerstel MPS 2 XL Twister is equipped
with a mVorx unit applied to resolve and mix the sam-
ples at 1300 rotations per min for 1 min both after
addition of methoxyamine-pyridine and N-methyl-N-
trimethylsilyltrifluoroacetamide.
Data analysis
Raw data obtained from GC/MS measurements were
processed by applying version 2.2 N-2013-01-15 of the in-
house developed software MetaboliteDetector [49]. The
peak identification was performed non-targeted with a
combined compound library for each GC column applied.
After processing, non-biological peaks and artefacts were
eliminated by the aid of blanks. Peak areas were normal-
ized to the corresponding internal standards (o-cresol or
ribitol) and derivatives were summarized. Data were fitted
sigmoidally after Boltzmann and uptake rates were deter-
mined using Origin9.0G software when applicable.
For leucine and phenylalanine fermentation products,
peak areas were estimated after normalization on the rela-
tive proportion of the specific quantification ion compared
to the total ion chromatogram but we cannot exclude dif-
ferences of the two compounds during drying or derivati-
zation procedures.
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